Notice is hereby given that the Office of Research Integrity (ORI) has made final findings of scientific misconduct in the following case: Weishu Y. Weiser, Ph.D., Harvard Medical School: On October 19, 1995, ORI found that Weishu Y. Weiser, Ph.D., formerly of the Harvard Medical School at Brigham and Women\'s Hospital, committed scientific misconduct by falsifying data in biomedical research supported by two Public Health Service (PHS) grants. Dr. Weiser has entered into a Voluntary Exclusion Agreement with ORI in which she has accepted ORI\'s finding and has agreed to exclude herself voluntarily, for the three (3) year period beginning October 19, 1995, from: (1) Participating in any Federal contracts or subcontracts and from eligibility for or involvement in Federal nonprocurement transactions (e.g., grants and cooperative agreements), as covered in 45 C.F.R. Part 76 and 48 C.F.R. Subparts 9.4 and 309.4 (Debarment Regulations); and (2) Serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. She has agreed to submit a letter to the Journal of Immunology and to the Proceedings of the National Academy of Sciences to retract the articles entitled \`\`Human recombinant migration inhibitory factor activates human macrophages to kill Leishmania donovani\'\' (Journal of Immunology 147:2006-2011, 1991), \`\`Recombinant migration inhibitory factor induces nitric oxide synthase in murine macrophages\'\' (Journal of Immunology 150:1908-1912, 1993), and \`\`Recombinant human migration inhibitory factor has adjuvant activity\'\' (Proceedings of the National Academy of Sciences 89:8049-8052, 1992).
